tradingkey.logo

Exagen Inc

XGN
View Detailed Chart
9.676USD
-0.704-6.78%
Market hours ETQuotes delayed by 15 min
217.81MMarket Cap
LossP/E TTM

Exagen Inc

9.676
-0.704-6.78%
Intraday
1m
30m
1h
D
W
M
D

Today

-6.78%

5 Days

-17.72%

1 Month

-11.23%

6 Months

+50.72%

Year to Date

+136.00%

1 Year

+283.52%

View Detailed Chart

TradingKey Stock Score of Exagen Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exagen Inc's Score

Industry at a Glance

Industry Ranking
22 / 78
Overall Ranking
136 / 4615
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
14.857
Target Price
+43.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Exagen Inc Highlights

StrengthsRisks
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 55.64M.
Undervalued
The company’s latest PE is -11.09, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 13.24M shares, increasing 15.13% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 681.62K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.96.

Exagen Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Exagen Inc Info

Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Ticker SymbolXGN
CompanyExagen Inc
CEOMr. John Aballi
Websitehttps://exagen.com/
KeyAI